# Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/istituto-scientifico-romagnolo-per-lo-studio-e-la-cura-dei-tumori/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 70.5 |
| Citations | 494,773 |
| City | Meldola |
| Country | IT |
| Description | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori is a research organisation in Meldola, IT. OpenAlex records 6,254 works and 494,773 citations for it. 984 researchers list it as their most recent affiliation. |
| Homepage | http://www.irst.emr.it/ |
| OpenAlex ID | https://openalex.org/I4210097834 |
| Researchers | 984 |
| ROR ID | https://ror.org/013wkc921 |
| Type | facility |
| Works | 6,254 |

## University papers

Showing 12 of 21.

- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial](https://scholariq.org/papers/afatinib-versus-placebo-for-patients-with-advanced-metastatic-non-small-cell/)
- [Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non/)
- [Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project](https://scholariq.org/papers/follicular-lymphoma-international-prognostic-index-2-a-new-prognostic-index-for/)
- [Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057/)
- [Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung/)
- [Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/ceritinib-versus-chemotherapy-in-patients-with-alk-rearranged-non-small-cell/)
- [2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up](https://scholariq.org/papers/2nd-esmo-consensus-conference-on-lung-cancer-early-stage-non-small-cell-lung/)
- [Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors](https://scholariq.org/papers/long-term-tolerability-of-prrt-in-807-patients-with-neuroendocrine-tumours-the/)
- [Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors](https://scholariq.org/papers/long-term-evaluation-of-renal-toxicity-after-peptide-receptor-radionuclide/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.